Stopping GLP-1 drugs can quickly erase cardiovascular benefits

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular ...

page 4 from 40